Article

Adjustability a plus for microkeratomes

Author(s):

Lynda Charters

Tampere, Finland-Both the M2 Single Use microkeratome and the M2 microkeratome with the new 90-?m head (Moria, Antony, France) have been performing well in clinical trials.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results
November 21st 2024

Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Recent changes to cornea: Preferred Practice Patterns
November 21st 2024

Recent changes to cornea: Preferred Practice Patterns

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Innovation and the clinician-scientist
November 20th 2024

Innovation and the clinician-scientist

FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye
November 19th 2024

FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye

© 2024 MJH Life Sciences

All rights reserved.